Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Oral drug therapy for erectile dysfunction.

H Padma-Nathan¹, F Giuliano

¹Department of Urology, Keck School of Medicine, University of Southern California Beverly Hills, California, USA.

The Urologic Clinics of North America

|June 14, 2001

Summary

New oral drugs for erectile dysfunction (ED) are emerging, building on sildenafil's success. Research is exploring various novel mechanisms and compounds for improved sexual pharmacotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Wnt/β-catenin pathway and cell adhesion deregulation in CSDE1-related intellectual disability and autism spectrum disorders.

Molecular psychiatry·2021

Same author

Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.

The British journal of dermatology·2018

Same author

Dermatological manifestations in cardiofaciocutaneous syndrome: a prospective multicentric study of 45 mutation-positive patients.

The British journal of dermatology·2018

Same author

Combined genetic approaches yield a 48% diagnostic rate in a large cohort of French hearing-impaired patients.

Scientific reports·2017

Same author

The spinal generator of ejaculation: Functional consequences of chronic spinalization and effect of substance P in anesthetized rats.

Neuroscience·2016

Same author

Genetic counselling difficulties and ethical implications of incidental findings from array-CGH: a 7-year national survey.

Clinical genetics·2015

Area of Science:

Pharmacology
Urology
Medicinal Chemistry

Background:

Oral medications are a primary treatment for erectile dysfunction (ED).
The success of sildenafil has spurred the development of numerous new ED therapies.
The field of sexual pharmacotherapy is rapidly advancing.

Purpose of the Study:

To review the current landscape and future directions of oral pharmacotherapy for erectile dysfunction.
To highlight emerging drug candidates and their mechanisms of action.

Main Methods:

Review of late and early phase III clinical trials for ED drugs.
Summary of preclinical and early clinical investigations into novel therapeutic targets.
Analysis of drug classes including PDE5 inhibitors, dopamine agonists, and nitric oxide donors.

Main Results:

Several novel agents, including apomorphine, IC351, and vardenafil, are in late-stage development.
Ongoing research targets phosphodiesterase inhibitors, cyclic AMP activators, and other pathways.
Diverse mechanisms are being explored, including alpha-adrenergic antagonists and endothelin antagonists.

Conclusions:

The pipeline for erectile dysfunction pharmacotherapy is robust, with multiple promising agents.
Future treatments will likely involve a wider range of mechanisms beyond PDE5 inhibition.
Advancements in sexual pharmacotherapy offer a positive outlook for patients with ED.

Related Experiment Videos